Gut health

At Genetic Analysis we are improving gut health every day!

Sign up for our gut microbiota newsletter

GA-map™ Dysbiosis Test on the Luminex instrument platform.
  • 9
    May
  • Image

Luminex and GA enter into an agreement

Genetic Analysis (GA) and Luminex Corp. Inc (Luminex) has entered into an agreement whereby GA will have the right to develop, market and sell the GA-map™ Dysbiosis Test on the Luminex instrument platform. Luminex is known for its "state of...

Read More
Bio-rad and Genetic Analysis
  • 29
    Nov
  • Image

Bio-Rad and Genetic Analysis Sign Agreement

Press Release: Bio-Rad to Commercialize Genetic Analysis’s GA-map Technology for the Detection of Gut Dysbiosis (Oslo and Hercules, Calif., 28 November 2016) Genetic Analysis (GA) and Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic  products, today...

Read More
low-fodmap-word-cloud
  • 18
    Oct
  • Image

GA-map™ Dysbiosis Test in new breakthrough for IBS patients

(Vienna, October 18, 2016) A low-FODMAP diet is now an established treatment for people with irritable bowel syndrome (IBS), but the diet is controversial and challenging to follow, and not all IBS sufferers have a positive response to the intervention....

Read More
NEC
  • 27
    Jul
  • Image

US Patent for Necrotizing Enterocolitis (NEC) Granted

  Press Release (Oslo, 27. July 2016) Genetic Analysis AS today announces that it has been granted a US patent (Patent No. 9376724) for a method for identifying neonates at risk for necrotizing enterocolitis. NEC is a gastrointestinal (GI) tract...

Read More
Bacteria IBD
  • 13
    Apr
  • Image

Microbiota in IBD  – ECCO 2016

(Amsterdam, March 16th 2016) Genetic Analysis AS has reported preliminary results in the pan European study “IBD Character” at the European Crohn’s and Colitis Organization’s (ECCO) Annual congress. Using the proprietary GA-map™ Dysbiosis Test, fecal microbiota dysbiosis patterns revealed that IBD...

Read More
Patent
  • 12
    Apr
  • Image

Genetic Analysis granted US and European patent for oligonucleotide probe set and methods of microbiota profiling

(Oslo, April 12th 2016) Genetic Analysis AS today announces that it has been granted a US patent (Patent No. 9243297) and a European patent (Patent No. 2652145) for its technology governing the oligonucleotide probe set and methods of microbiota profiling....

Read More
GA-map results presented at ECCO
  • 15
    Mar
  • Image

GA-map results presented at ECCO

Results from a Pan European study, where the GA–map™ Dysbiosis Test is used to determine microbiota profiles, will be presented at the European Crohn’s and  Colitis Organization’s Annual congress (ECCO), hold in Amsterdam in March 16 -19 2016. ECCO’s focus...

Read More
Biohit-healthcare
  • 6
    Jan
  • Image

Genetic Analysis signs distribution agreement for China and Finland

(Oslo, 05 January 2016) Genetic Analysis has entered into an exclusive distribution agreement for the Chinese and Finnish markets with Biohit Oyj (Biohit), a Finnish biotechnology and diagnostic company. Biohit also invests in Genetic Analysis through a share exchange agreement,...

Read More
Microbiota analysis
  • 15
    Sep
  • Image

Make sure to choose the proper technology for gut microbiota analysis

Understanding the composition of complex environmental samples like gut microbiota content, has been one of the greatest biotechnological challenges of the 21th century. New technologies have gained access to information about bacterial composition in the gut. However, as the amount of...

Read More
Anti-TNF responders and non-responders
  • 31
    Aug
  • Image

Gut microbiota in anti-TNF response in ulcerative colitis

In a poster presented at ICMI in Berlin this summer, Magnusson et al from the Sahlgrenska Academy, Sweden, presented promising results that Anti-TNF therapy responders and non-responders display different  Antimicrobial peptides (AMPs) expression and microbiota profiles before start of therapy. Knowing that...

Read More